Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016

Acta Oncol. 2020 Jan;59(1):101-105. doi: 10.1080/0284186X.2019.1652765. Epub 2019 Aug 20.

Authors

Alexander Fosså^{1

2}, Knut Smeland¹, Unn-Merete Fagerli³, Renate B Galleberg⁴, Hanne S Bersvendsen⁵, Harald Holte^{1

2}

Affiliations

¹ Department of Oncology, Oslo University Hospital, Oslo, Norway.
² KG Jebsen Centre for B-Cell Malignancies, University of Oslo, Oslo, Norway.
³ Department of Oncology, St. Olav's Hospital, Trondheim, Norway.
⁴ Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.
⁵ Department of Oncology, University Hospital of Northern Norway, Tromsø, Norway.

PMID: 31429371
DOI: 10.1080/0284186X.2019.1652765

No abstract available

Publication types

Letter
Multicenter Study

MeSH terms

Adult
Allografts
Antineoplastic Agents, Immunological / therapeutic use*
Brentuximab Vedotin / therapeutic use*
Female
Hodgkin Disease / mortality
Hodgkin Disease / pathology
Hodgkin Disease / therapy*
Humans
Male
Middle Aged
Norway
Recurrence
Stem Cell Transplantation
Survival Analysis
Transplantation, Autologous
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Brentuximab Vedotin